ReviewPediatric nephrology (Berlin, Germany)2026
Biomarkers of kidney involvement in paediatric IgA vasculitis: a systematic review and meta-analysis.
Review in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Corticosteroids in childhood IgA vasculitis: can early therapy mask kidney involvement?Pediatric nephrology (Berlin, Germany) · 2026Article
- Predictive value of neutrophil-to-lymphocyte ratio and fibrinogen degradation products for renal involvement in pediatric immunoglobulin A vasculitis.Translational pediatrics · 2026Article
- Cytokine-augmented risk stratification for six-month incident nephritis in children with IgA vasculitis.Frontiers in pediatrics · 2026Article
- Association of the inflammation indicators with multiple system involved of immunoglobulin A vasculitis in children.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIgA vasculitis nephritis (IgAVN) develops in 20-80% of patients with IgA vasculitis (IgAV), yet diagnosis is often delayed. Readily available biomarkers can help identify patients at risk earlier.
objectiveTo conduct a systematic review and meta-analysis of all available serum and urinary biomarkers to evaluate their prognostic potential in predicting IgAVN in paediatric patients. DATA SOURCES: A comprehensive search was performed in PubMed, EMBASE and Cochrane Library on November 9, 2024, covering publications from inception. The search strategy included three domains: paediatric population, IgAV diagnosis and studied biomarkers. No language or additional restrictions were applied. STUDY ELIGIBILITY CRITERIA AND
participantsWe included original retrospective, prospective and cross-sectional studies that involved paediatric IgAV patients and reported biomarker levels in patients with and without nephritis. Two reviewers independently screened studies, and a third reviewer resolved conflicts. STUDY APPRAISAL AND SYNTHESIS
methodsData extraction was performed by two independent reviewers. A random-effects model was used for analysis. The review followed PRISMA guidelines, and study quality was assessed using the QUIPS tool. Outcomes were reported as mean or standardised mean differences with 95% confidence intervals (CI). Where possible, odds ratios (OR) and diagnostic performance measures were also evaluated.
resultsOf 10,611 records screened, 129 studies including 23,726 patients were included. The neutrophil-to-lymphocyte ratio (NLR) was significantly higher in patients with nephritis (0.48; 95% CI 0.04-0.93), with notable effects in the Turkish population (0.86; 95% CI 0.19-1.52) but not in the Chinese population (- 0.02; 95% CI - 0.75-0.72). The platelet-to-lymphocyte ratio (PLR) showed a similar pattern, being higher in the Turkish subgroup (21.9; 95% CI 9.64-34.16) and lower in the Chinese subgroup (- 6.75; 95% CI - 11.27-2.22). A positive faecal occult blood test (FOBT) was associated with increased odds of kidney involvement (OR 2.04; 95% CI 1.05-3.96). LIMITATIONS: This study has limitations, including the predominance of retrospective data, limited reporting of diagnostic accuracy metrics (e.g. sensitivity, specificity), and substantial inter-study heterogeneity in nephritis definitions, measurement methods and study populations, which restrict firm conclusions about biomarker performance. CONCLUSIONS AND IMPLICATIONS OF KEY
findingsWhile statistically significant biomarker associations exist, clinically actionable predictors of IgAVN remain lacking. NLR, PLR and FOBT warrant prospective validation in multicentre cohorts with standardised protocols. SYSTEMATIC REVIEW REGISTRATION NUMBER: CRD42024593928.
Indexed as
Identifiers
42247000What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.